Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ

• Published in: NPJ breast cancer Vol. 10; no. 1; pp. 71 - 9
• Main Authors: Greenwood, Heather I., Maldonado Rodas, Cristian K., Freimanis, Rita I., Glencer, Alexa C., Miller, Phoebe N., Mukhtar, Rita A., Brabham, Case, Yau, Christina, Rosenbluth, Jennifer M., Hirst, Gillian L., Campbell, Michael J., Borowsky, Alexander, Hylton, Nola, Esserman, Laura J., Basu, Amrita
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 04-08-2024; Nature Publishing Group; Nature Portfolio
• Subjects: 692/53/2422; 692/699/67/1347; Biomedical and Life Sciences; Biomedicine; Breast cancer; Cancer Research; Cell Biology; Human Genetics; Magnetic resonance imaging; Oncology; Surveillance
• ISSN: 2374-4677; 2374-4677
• DOI: 10.1038/s41523-024-00677-9

New approaches are needed to determine which ductal carcinoma in situ (DCIS) is at high risk for progression to invasive ductal carcinoma (IDC). We retrospectively studied DCIS patients who declined surgery (2002–2019), and received endocrine therapy (ET) and breast MRI. Baseline MRI and changes at 3 months and 6 months were analyzed by recursive partitioning to stratify IDC risk. Sixty-two patients (63 DCIS; 1 bilateral) with a mean follow-up of 8.5 years were included. Fifty-one percent remained on active surveillance (AS) without evidence of IDC, with a mean duration of 7.6 years. A decision tree based on MRI features of lesion distinctness and background parenchymal enhancement (BPE) at baseline and change after 3 months of ET stratified patients into low, intermediate, and high risk for progression to IDC. MRI imaging features in patients treated with ET and undergoing AS, may help determine which DCIS lesions are at low versus high risk for IDC.